生产企业：Immuneering
IMM-1-104 (atebimetinib) is Immuneering's lead product candidate, an oral, once-daily deep cyclic inhibitor of MEK. It is in clinical development for pancreatic cancer — including first-line metastatic pancreatic ductal adenocarcinoma (Phase 3) — and for NSCLC, both as monotherapy and in combination with chemotherapy such as modified gemcitabine/nab-paclitaxel.
IMM-1-104 (atebimetinib) is Immuneering's lead product candidate, an oral, once-daily deep cyclic inhibitor of MEK. It is in clinical development for pancreatic cancer — including first-line metastatic pancreatic ductal adenocarcinoma (Phase 3) — and for NSCLC, both as monotherapy and in combination with chemotherapy such as modified gemcitabine/nab-paclitaxel.
Oral, once-daily deep cyclic inhibitor of MEK; allosteric inhibitor of MEK1/2 that chronically suppresses MAPK signaling.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
